Neil Cataldi From Blueprint Discusses Sanara MedTech
Summary
- SMTI's stock has fallen in the wake of a recent equity raise.
- Neil Cataldi from Blueprint Capital discusses what he thinks the market is missing.
- Recent addition to their "approved hospital" list should drive significant near-term growth.
Neil Cataldi from Blueprint Capital discusses his investment thesis for Sanara MedTech (NASDAQ:SMTI). Sanara is growing quickly, and Neil thinks continued growth in their product portfolio and hospitals they are approved to sell in will drive continued accelerated growth and long-term compounding.
Chapters
0:00 Intro
1:00 Sanara overview
5:30 How is Sanara increasing their hospital reach?
14:25 Discussing management
21:10 Related party risks
33:20 Breaking down SMTI's growth
42:45 Sanara's telehealth ambitions
1:01:10 Closing thoughts
This article was written by
Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Recommended For You
Comments (2)
